BidaskClub upgraded shares of Apellis Pharmaceuticals (NASDAQ:APLS) from a hold rating to a buy rating in a report released on Wednesday, BidAskClub reports.
Several other equities analysts have also recently weighed in on the company. Roth Capital increased their price target on Apellis Pharmaceuticals from $50.00 to $73.00 and gave the company a buy rating in a report on Tuesday, December 15th. Smith Barney Citigroup upped their price objective on Apellis Pharmaceuticals from $53.00 to $67.00 in a research note on Monday, November 23rd. ValuEngine lowered Apellis Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, November 17th. Zacks Investment Research upgraded Apellis Pharmaceuticals from a strong sell rating to a hold rating and set a $27.00 price objective for the company in a research note on Friday, October 30th. Finally, BMO Capital Markets upped their price objective on Apellis Pharmaceuticals from $57.00 to $66.00 and gave the stock an outperform rating in a research note on Tuesday, December 1st. Six equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $103.24.
NASDAQ APLS opened at $55.44 on Wednesday. The business’s fifty day moving average price is $46.26 and its 200-day moving average price is $34.85. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of -7.47 and a beta of 1.43. The company has a debt-to-equity ratio of 3.34, a current ratio of 9.86 and a quick ratio of 9.86. Apellis Pharmaceuticals has a 1-year low of $16.85 and a 1-year high of $56.80.
Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Saturday, November 7th. The company reported ($1.79) earnings per share for the quarter, missing the consensus estimate of ($1.58) by ($0.21). The firm had revenue of $0.65 million during the quarter. Equities research analysts anticipate that Apellis Pharmaceuticals will post -5.96 EPS for the current year.
In other news, Director A. Sinclair Dunlop sold 25,000 shares of the firm’s stock in a transaction dated Monday, December 7th. The stock was sold at an average price of $50.59, for a total transaction of $1,264,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 5,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $34.46, for a total value of $172,300.00. Following the transaction, the chief executive officer now owns 1,083,079 shares of the company’s stock, valued at approximately $37,322,902.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 133,469 shares of company stock valued at $6,334,910. Company insiders own 9.50% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 44.7% in the 2nd quarter. Vanguard Group Inc. now owns 4,388,181 shares of the company’s stock valued at $143,318,000 after acquiring an additional 1,354,710 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Apellis Pharmaceuticals by 33.4% in the 3rd quarter. Jennison Associates LLC now owns 2,837,786 shares of the company’s stock valued at $85,616,000 after acquiring an additional 710,708 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Apellis Pharmaceuticals by 396.0% in the 2nd quarter. Bank of Montreal Can now owns 334,830 shares of the company’s stock valued at $10,627,000 after acquiring an additional 267,330 shares during the last quarter. Man Group plc lifted its holdings in shares of Apellis Pharmaceuticals by 1,885.4% in the 2nd quarter. Man Group plc now owns 257,346 shares of the company’s stock valued at $8,405,000 after acquiring an additional 244,384 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Apellis Pharmaceuticals by 114.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 446,936 shares of the company’s stock valued at $13,484,000 after acquiring an additional 238,833 shares during the last quarter. Hedge funds and other institutional investors own 67.40% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Featured Article: Why is momentum important to successful trading?